Comparison of FOXO3 and FOXO1 induced transcriptomic changes underline the importance of the metabolic checkpoint in B-ALL maintenance and potential value of screening patient-derived blasts for response to agents such as FOXO agonists or inhibitors of glycolysis. The gene discussed is FOXO3; the disease is acute lymphoblastic leukemia.